| RDY Stock | | | USD 14.90 0.07 0.47% |
COO
Mr. Erez Israeli is a Chief Operating Officer and Global Head of Generics PSAI of the Company. In a career spanning over 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including Vice President Marketing Sales for North America, Vice President Asia Operations, President Teva API, Group Executive Vice President, Head of Global Quality, and President CEO Growth Markets. since 2019.
| Age | 53 |
| Tenure | 6 years |
| Address | 8-2-337, Road No. 3, Hyderabad, India, 500034 |
| Phone | 91 40 4900 2900 |
| Web | https://www.drreddys.com |
Dr Reddys Management Efficiency
The company has Return on Asset of
0.104 % which means that on every $100 spent on assets, it made $0.104 of profit. This is way below average. In the same way, it shows a return on shareholders' equity
(ROE) of
0.1927 %, implying that it generated $0.1927 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to 0.11 in 2025.
Return On Capital Employed is likely to drop to 0.11 in 2025. At this time, Dr Reddys'
Total Assets are fairly stable compared to the past year.
Other Assets is likely to rise to about 8.6
B in 2025, whereas
Intangible Assets are likely to drop slightly above 24.7
B in 2025.
Dr Reddys Laboratories has 20.02
B in debt with debt to equity
(D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. Dr Reddys Laboratories has a current ratio of 1.94, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for RDY to invest in growth at high rates of return.
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people. Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA. It is located in 8-2-337, Road No. 3, Hyderabad, India, 500034 and employs 27,048 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
Dr Reddys Laboratories Leadership Team
Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDY. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MARC KIKUCHI, Chief Executive Officer, North America Generics | |
| Krishna MS, Global Council | |
| Venkata MBA, CEO Council | |
| Leo Puri, Non-Executive Independent Director | |
| Sandeep Poddar, Compliance Officer, Company Secretary | |
| Satish Reddy, Co-Chairman of the Board | |
| Patrick Aghanian, Chief Executive Officer, European Generics | |
| Sumera Hasham, Senior officer | |
| Arunabha RayChaudhuri, Head Director | |
| Jayanth Sridhar, Global Council | |
| Sanjay BTech, Global VP | |
| Prasad Menon, Lead Non-Executive Independent Director | |
| K Krishnan, Additional Independent Director | |
| Shikha Sharma, Non-Executive Independent Director | |
| Milan Kalawadia, CEO Council | |
| Bharat Doshi, Non-Executive Independent Director | |
| Gunupati BE, MD CoChairman | |
| Raymond Vre, Global Head of Biologics | |
| Bruce Carter, Non-Executive Independent Director | |
| M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) | |
| Parag Agarwal, Chief Financial Officer - Designate | |
| MPharm MS, Senior President | |
| Archana Bhaskar, Chief Human Resource Officer | |
| Erez MBA, CEO Council | |
| MS BTech, Chairman Council | |
| Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients | |
| Penny Wan, Additional Independent Director | |
| G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director | |
| P Yugandhar, Global Head of Supply Chain | |
| Sushrut Kulkarni, Global Council | |
| Sauri Gudlavalleti, Global Head of Integrated Product Development Organization | |
| YUGANDHAR PUVVALA, Global Head of Supply Chain | |
| K Singh, Chief Compliance Officer, Company Secretary | |
| Allan Oberman, Non-Executive Independent Director | |
| Anil Namboodiripad, Global Head of Proprietary Products | |
| Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE | |
| SANJAY SHARMA, Global Head of Manufacturing | |
| Sridar Iyengar, Non-Executive Independent Director | |
| Ganadhish Kamat, Executive Vice President and Global Head-Quality | |
| Vivek Mittal, Interim Compliance Officer, General Counsel | |
| Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI | |
| Kalpana Morparia, Non-Executive Independent Director | |
| Kumar Singh, Compliance Secretary | |
| Richa Periwal, Head Analytics | |
| Mannam Venkatanarasimham, Deputy Council | |
| Deepak MBA, CEO Council | |
| Bhethanabottla Phanimitra, Chief Council | |
| MBA MBA, CEO Council | |
| Mukesh Rathi, Chief Digital and Information Officer | |
RDY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to
measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to
predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.